PVR Reduced in Adults With HFpEF, Pulmonary Hypertension

Published Date: 10 Apr 2026

In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients with combined postcapillary and precapillary pulmonary hypertension and HFpEF.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot